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Human metapneumovirus (hMPV) is a major cause of upper and lower respiratory-tract infection in
infants, the elderly and immunocompromised individuals. Virus-directed cellular immunity elicited
by hMPV infection is poorly understood, in contrast to the phylogenetically and clinically related
pathogen human respiratory syncytial virus (hRSV). In a murine model of acute lower respiratory-
tract infection with hMPV, we demonstrate the accumulation of gamma interferon (IFN-c)-
producing CD8+ T cells in the airways and lungs at day 7 post-infection (p.i.), associated with
cytotoxic T lymphocytes (CTLs) directed to an epitope of the M2-1 protein. This CTL immunity
was accompanied by increased pulmonary expression of Th1 cytokines IFN-c and interleukin
(IL)-12 and antiviral cytokines (IFN-b), as well as chemokines Mip-1a, Mip-1b, Mig, IP-10 and
CX3CL1. There was also a moderate increase in Th2-type cytokines IL-4 and IL-10 compared
with uninfected mice. At 21 days p.i., a strong CTL response could be recalled from the spleen. A
similar pattern of CTL induction to the homologous M2-1 CTL epitope of hRSV, and of cytokine/
chemokine induction, was observed following infection with hRSV, highlighting similarities in the
cellular immune response to the two related pathogens.
INTRODUCTION
Human metapneumovirus (hMPV) was first isolated in
2001 from children with respiratory-tract disease that was
not attributable to other previously known respiratory
viruses (van den Hoogen et al., 2001). Although recently
identified, the virus is thought to have circulated in the
human population for at least 50 years (van den Hoogen
et al., 2004; Williams et al., 2006) and infections have been
reported globally (Boivin et al., 2002; Esper et al., 2003;
Mao et al., 2008; Nissen et al., 2002; Pierangeli et al., 2007;
Stockton et al., 2002). hMPV is a single-stranded, negative-
sense RNA virus, classified in the family Paramyxoviridae
alongside other mammalian respiratory pathogens, includ-
ing human respiratory syncytial virus (hRSV) and human
parainfluenza viruses. Clinically, hMPV infection produces
disease symptoms similar to those observed for hRSV
infection, ranging from mild respiratory illness to bronch-
iolitis and pneumonia, although hMPV disease is less
rampant (van den Hoogen et al., 2003, 2004). Young
children, the elderly and immunocompromised individuals
are particularly susceptible to hMPV-associated disease,
emphasizing the need to understand the role of antiviral
immunity in the control of infection. Several studies have
indicated a strong association between hMPV disease and
asthma in both children (Garcia-Garcia et al., 2007; Peiris
et al., 2003; Tauro et al., 2008) and adults (Williams et al.,
2005), implicating hMPV in ongoing or long-term adverse
effects.
Clinical infection with hMPV and hRSV in humans occurs
throughout life, despite the fact that most individuals
sustain humoral immune responses to both hMPV
(Ebihara et al., 2004; van den Hoogen et al., 2004) and
hRSV (Baumeister et al., 2003; Ward et al., 1983). Whilst
the cellular immune response following hRSV infection is
well-understood in humans (Welliver, 2008) and in animal
models (Hall et al., 1986; Rutigliano et al., 2005), in hMPV
infection it is incompletely described. Similarities to hRSV
suggest that CD8+ T cells are likely to be necessary to
resolve hMPV infection in humans (Hall et al., 1986). A
role for cytotoxic T lymphocytes (CTLs) in the control of
hMPV infection is supported by in vivo mouse studies
showing increased hMPV titres in T cell-depleted mice3These authors contributed equally to this work.
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(Alvarez et al., 2004), and protection against infection by
adoptive transfer of hMPV-specific CTLs (Melendi et al.,
2007) and hMPV-directed T-cell vaccines (Herd et al.,
2006). However, the onset of the CTL-mediated immune
response and the induction of immunoregulatory cytokines
following infection with hMPV require further study.
In the present study, we examined the induction of the CTL-
mediated immune response and the induction of cytokines
and chemokines in hMPV-infected mice, and compared
these with the responses induced in hRSV-infected mice. We
demonstrate that hMPV infection results in an accumu-
lation of virus-specific cytotoxic and gamma interferon
(IFN-c)+CD8+ effector T cells in the airways and lungs at
7 days post-infection (p.i.). This T-cell immunity was
associated with increased expression of Th1-type [interleukin
(IL)-12 and IFN-c] and antiviral (IFN-b) cytokines and the
chemokines Mip-1a (CCL3), Mip-1b (CCL4), Mig (CXCL9),
IP-10 (CXCL10) and CX3CL1 (fractalkine). A moderate
increase in the expression of Th2-type cytokines (IL-4 and
IL-10) was also observed. No effector CTLs were detected in
the regional lymph nodes or spleen at 7 days p.i., although a
strong memory response could be recalled from the spleen at
21 days p.i. A similar pattern of cell-mediated responses was
observed in hRSV-infected mice, highlighting the similarities
in immunity to these respiratory pathogens. We discuss these
findings in the context of other studies comparing hMPV and
hRSV infection (Guerrero-Plata et al., 2005; Huck et al.,
2007). The findings support our previous observation that a
CTL-epitope vaccine can protect against hMPV infection in
mice (Herd et al., 2006) and offer encouragement for the
prospect of developing effective immunotherapies.
RESULTS
Virus infection of the lung
BALB/c mice were infected intranasally with 105 TCID50 of
either hMPV or hRSV. At 1 and 2 days p.i., significant weight
loss was evident in hMPV-infected mice, but not in hRSV-
infected mice (Fig. 1a). However, no other signs of illness
were detected in either group. At 5 days p.i., viral load was
102.9 and 103.2 TCID50 per left lung for hMPV- and hRSV-
infected mice, respectively (Fig. 1b). At 8 days p.i., viral load
was below the detection limit of 101.6 TCID50 per left lung
(data not shown). The lungs of infected mice showed
pathology consistent with interstitial pneumonia (i.e. bron-
chial epithelial-cell damage and infiltration by inflammatory
cells), with more severe pathology evident in hRSV-infected
lungs (Fig. 1c). Cellular infiltration occurred predominantly
around and within the alveoli and within the airways at
approximately 5 days p.i. with either hMPV or hRSV.
Accumulation of virus-specific IFN-c+CD8+ T cells
in airways and lungs
An important CTL-mediated effector mechanism during
virus infection is secretion of antiviral cytokines such as
IFN-c. We evaluated ex vivo virus-specific CTL activity
from mouse lungs after infection with either hMPV or
hRSV. Cells from the airways (bronchoalveolar lavage;
BAL), lung tissue, regional lymph nodes and spleen were
tested at 7 days p.i. for the presence of CD8+ T cells that
produced IFN-c specifically in response to short-term
stimulation with virus-specific peptide. For hMPV-infected
mice, CD8+ T cells from the airways (14%) and lungs
(18%), but not the lymph nodes or spleen, produced
IFN-c when stimulated with ‘GYI’ epitope peptide (insets,
Fig. 2a). A similar pattern of CD8+ T cells was seen for
hRSV-infected mice when stimulated with ‘SYI’ epitope
peptide (insets, Fig. 2b).
hMPV-specific cytotoxic T cells in airways and
lungs
Antiviral CTLs are important for resolution of infection
with a number of viruses, including hRSV. To determine
whether CTL activity was induced by hMPV infection and
whether it was similar to that induced by hRSV infection,
cells were collected from the airways (BAL), lungs, draining
lymph nodes and spleen at 7 days p.i. and were tested in a
mini-CTL assay. Airway and lung cells from hMPV-
infected mice killed ‘GYI’-target cells (14 and 7%
cytotoxicity at an effector-to-target cell ratio of 12 : 1,
respectively) (Fig. 2a). Similarly, airway and lung cells from
hRSV-infected mice killed ‘SYI’-target cells (34 and 12%
cytotoxicity, respectively) (Fig. 2b). In contrast, cells from
the regional lymph nodes and spleen of virus-infected mice
failed to kill target cells. The presence of detectable CTL
activity correlated with the induction of IFN-c+CD8+ T
cells (insets, Fig. 2).
To investigate whether virus-specific memory CTLs were
present, cells were collected from the spleen at 21 days p.i.,
restimulated in vitro with virus-specific peptide for 6 days
and then tested in a mini-CTL assay. Restimulated spleen
cells from hMPV-infected mice and from hRSV-infected
mice showed substantial killing of peptide-labelled target
cells (40–60%), even at the lowest effector-to-target cell
ratio of 2 : 1 (Fig. 3).
In summary, pulmonary infection with hMPV induces an
effector CTL response detectable ex vivo in cells from the
airways and lungs, but not from regional lymph nodes or
spleen, at 7 days p.i. The response is similar to, but slightly
lower than, that seen for hRSV infection. The data also
indicate that a memory CTL response specific for the CTL
epitopes in the M2 proteins could be recalled at 21 days p.i.
hMPV infection modifies the expression of
cytokines and chemokines in lungs
The production of cytokines and chemokines plays a vital
role in mediating recovery from virus infections (reviewed
by Ramshaw et al., 1997). It was thus relevant to ask
whether antiviral and/or immunoregulatory cytokine
and chemokine expression was altered following hMPV
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infection. RT-PCR analysis indicated that mRNAs encod-
ing the Th1-type (IL-12) and Th2-type (IL-4 and IL-10)
cytokines were expressed at .10-fold higher levels in the
lungs of hMPV- and hRSV-infected mice compared with
uninfected mice (Fig. 4). In addition, mRNAs encoding
T-cell attractant and/or pro-inflammatory chemokines
(Mip-1b, Mig and CX3CL1) were expressed at .30-fold
higher levels in virus-infected mice compared with
uninfected mice. ELISA analysis of lung homogenates
showed that levels of the Th1-type (IFN-c) and antiviral
(IFN-b) cytokines, as well as chemokines (Mip-1a and IP-
10), were enhanced in virus-infected mice compared with
uninfected mice (Fig. 5).
In conclusion, these data suggest that hMPV infection
creates a local milieu conducive to development of both
innate and adaptive immune responses. Furthermore,
within the context of the cytokines and chemokines
assayed, the outcome of hMPV infection parallels that of
hRSV infection.
DISCUSSION
Human metapneumovirus is an important respiratory
pathogen causing infections worldwide, with symptoms
similar to those seen in hRSV and parainfluenza virus
infections (van den Hoogen et al., 2004). The strong
association between hMPV infection and asthma in both
children (Garcia-Garcia et al., 2007; Peiris et al., 2003) and
adults (Williams et al., 2005), and the ability of hMPV
infection to exacerbate hRSV disease (Bosis et al., 2005;
Semple et al., 2005), illustrate the need to improve our
understanding of hMPV-induced T-cell immunity, par-
ticularly as a prelude to therapeutic intervention. As hMPV
can establish productive infection in the upper and lower
respiratory tract (Alvarez et al., 2004; Hamelin et al., 2005;
van den Hoogen et al., 2001), hMPV-expressed proteins
have the potential to function as targets of CD8+ CTL
responses. Similarities to other, more widely studied
viruses, such as hRSV (Braciale, 2005), suggest that this
process may be associated with reduced virus replication
and the duration or intensity of infection.
In the present study, intranasal infection of mice with
hMPV was used as a model for natural infection in
humans. The kinetics of virus replication, the self-limiting
infection and the early onset of inflammation are similar to
the responses induced by hRSV infection and are in
accordance with previous studies (Hamelin et al., 2005;
Huck et al., 2007). Weight loss was more severe after
hMPV infection, in accord with findings elsewhere (Huck
et al., 2007). Our observation that histopathology of lungs
was more severe after hRSV infection than hMPV infection
Fig. 1. hMPV and hRSV infection. BALB/c mice (n54 per group)
were infected intranasally with 105 TCID50 of either hMPV or
hRSV (&) or were uninfected (h). (a) Weight was monitored daily,
and results are shown as mean percentage weight change ±SEM
(*P,0.05). (b) Viral load in lungs at 5 days p.i. was determined by
immunofocus assay. Results are shown as log10(TCID50 per left
lung). The solid line represents the geometric mean. (c)
Histopathological changes in lungs at 5 days p.i. were examined
after haematoxylin/eosin staining. Representative sections are
shown for uninfected, hMPV- and hRSV-infected mice (magnifica-
tion, 10).
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(Fig. 1c) is in contrast to that of Huck et al. (2007) and may
reflect the virulence of hMPV, although both laboratories
used primary hMPV strain A isolated from human
patients. We further extend the findings on T-cell
recruitment (Huck et al., 2007) to show no major
difference in accumulation of epitope-specific CTLs in
the lung airways between hMPV and hRSV infection (Fig.
2). The CTL epitope (‘GYI’) in the M2-1 protein of hMPV
occurs at a near-identical position to the CTL epitope
(‘SYI’) in the M2 protein of hRSV, and was therefore
chosen to monitor cell-mediated immunity. At 7 days p.i.,
accumulation of CD8+ T cells capable of producing IFN-c
in response to stimulation with the ‘GYI’ epitope occurred
in the airways and lungs. This was associated with CTL
activity specific for target cells expressing the ‘GYI’ epitope.
No such response could be detected in the regional lymph
nodes or spleen at 7 days p.i., supporting the concept that a
local response at the site of infection may be a first line of
defence in CTL-mediated virus control during the early
stages of infection. Although no virus-specific CTL activity
was evident in the spleen at 7 days p.i., a strong response
could be recalled at 21 days p.i. (Fig. 3), reflecting that seen
in a previous study (Alvarez & Tripp, 2005). This suggests
that a systemic spread of response from the lung and
airways may be associated with the development of
memory.
Our studies do not support the delay in the onset of CTL
responses following murine infection reported previously
(Alvarez et al., 2004). This discrepancy may reflect that
these authors examined splenic and not airway mono-
nuclear cells. The CTL response that we observe following
experimental infection was recorded 3 days earlier than
reported by Melendi et al. (2007). Our findings are in
accord with those showing that CD8+ T cells are required
for clearance of primary hMPV from the lung; for a
number of weeks after primary infection, mice are
protected by virtue of this CD8+ T-cell response against
further hMPV challenge (Kolli et al., 2008). Studies
elsewhere (Alvarez & Tripp, 2005; Kolli et al., 2008) show
that CD4+ T cells, as well as CD8+ T cells, play an antiviral
role, and the two subsets act together synergistically to
effect hMPV clearance from the lung. Depletion studies,
however, indicate that protection from reinfection can be
mediated by an intact CD8+ T-cell compartment alone in
the absence of CD4+ T cells and of neutralizing antibodies
(Kolli et al., 2008). This is in contrast to hRSV primary
infection of mice, in which absence of CD8+ T cells
provided a greater protective effect against disease than an
absence of CD4+ T cells (Graham et al., 1991; Kolli et al.,
2008). Similarly, whilst CD8+ T cells appear to be
sufficient to control hMPV reinfection, in hRSV reinfec-
tion CD4+ T cells (and antibody) are required (Kolli et al.,
2008).
Whilst CD4+ and CD8+ CTL responses serve to clear
current infection and protect against future infection, they
also contribute to clinical disease and lung pathology,
although the pathophysiology is not well-understood (Kolli
et al., 2008). The effects are less severe if CD4+ rather than
Fig. 2. hMPV and hRSV induce virus-specific cytotoxic and IFN-c+CD8+ effector T cells in airways and lungs. Mice (n54 per
group) were infected intranasally with 105 TCID50 of either hMPV (a) or hRSV (b). Cells from the airways (BAL), lungs, regional
lymph nodes and spleen were collected at 7 days p.i., pooled per group and evaluated ex vivo for cytotoxicity against target
cells with (&) or without (h) virus-specific M2 peptide. Results are expressed as percentage cytotoxicity. Numbers represent
peptide-specific cytotoxity at an effector-to-target cell ratio of 12 : 1. Bar graphs (insets) represent IFN-c+CD8+ T cells as a
percentage of total CD8+ T cells (from four mice per group, pooled) after 6 h stimulation with (filled bars) or without (empty
bars) M2 peptide.
Cellular immune response in hMPV infection
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CD8+ cells are depleted (Alvarez et al., 2004; Kolli et al.,
2008) and a recent paper reported that hMPV infection was
more severe in aged mice, a finding that corresponded to,
among other things, an increase in CD4+ T cells being
recruited to the respiratory tract (Darniot et al., 2009). This
suggests that CD8+ cells are not primarily responsible for
the detrimental effects of immune-response induction
following natural infection with hMPV, and underscores
a putative advantage for a Th1 bias in the cellular immune
response to hMPV infection.
In this study, hMPV infection was seen to enhance the
expression of Th1-type (IL-12, IFN-c) and antiviral (IFN-b)
cytokines. Most laboratories agree on the upregulation of
IFN-c after hMPV infection (Guerrero-Plata et al., 2005;
Hamelin et al., 2005; Huck et al., 2007). In the current
study, the local accumulation of CD8+ IFN-c-producing
cells correlated with the hMPV-directed cytolytic activity
of mononuclear cells at these sites (Fig. 2). Additionally,
IFN-c coordinates a diverse array of cellular programmes
that will impact upon virus-infected cells through transcrip-
tional regulation of immunologically relevant genes.
Only moderate (Fig. 4) or no (Guerrero-Plata et al., 2005;
Huck et al., 2007) upregulation of Th2-type cytokine IL-10
was recorded following infection, consistent with the
interpretation of a Th1-biased response. In contrast,
substantially augmented IL-10 expression reported by
Alvarez & Tripp (2005) at 7–28 days suggests induction
of a Th2-type response in the later stages of infection in
their model. This latter result is in accord with Barends
et al. (2002), who demonstrated that some paramyxoviruses,
such as hRSV, enhance a Th2 response.
We found that hMPV and hRSV had similar potency in
induction of pro-inflammatory cytokines in the context of
those cytokines that we studied and at the time point that
we examined (7 days p.i.). Guerrero-Plata et al. (2005)
showed that, whilst hRSV and hMPV infections induced
similar production of some cytokines, a further set of pro-
inflammatory cytokines (IL-1a, IL-1b, IL-6 and TNF-a)
were induced differentially. In accord with findings
elsewhere (Douville et al., 2006), they concluded that
hMPV induces lower levels of canonical inflammatory
cytokines than hRSV, although hMPV was a more potent
inducer of others, e.g. granulocyte–macrophage colony-
stimulating factor, IFN-c and IFN-a. We show enhanced
expression of several chemokines (Mip-1a, Mip-1b,
Mig, IP-10 and CX3CL1) following hMPV infection
(Figs 4 and 5). Upregulation of Mip-1a (CCL3) was also
recorded by Hamelin et al. (2005). Notably, peak levels of
Mip-1a in their study occurred at the height of virus
infection (5–7 days p.i.). These results are in contrast to
those of Guerrero-Plata et al. (2005), who did not record
the production of Mip-1a following hMPV infection.
Fig. 3. hMPV and hRSV induce virus-specific memory CTLs in the
spleen at 21 days p.i. Mice (n54 per group) were infected
intranasally with 105 TCID50 of either hMPV (a) or hRSV (b) or
were uninfected. Spleen cells were harvested at 21 days p.i.,
pooled per group and restimulated in vitro with virus-specific M2
peptide for 6 days before being evaluated for cytotoxicity against
target cells with (&) or without (h) the appropriate peptide. Results
are expressed as percentage cytotoxicity. Numbers represent
peptide-specific cytotoxity at an effector-to-target cell ratio of 12 : 1.
Fig. 4. Immunoregulatory cytokine and chemokine expression is
upregulated in lungs. Mice (n53 per group) were infected
intranasally with 105.7 p.f.u. of either hMPV (shaded bars) or
hRSV (filled bars) or were uninfected. Cytokine and chemokine
expression in the lungs at 7 days p.i. was quantified by real-time
PCR. Results are expressed as fold change over mRNA levels of
these cytokines and chemokines in the lungs of uninfected mice
(mean±SEM). Cytokines are interleukins and chemokines are Mip-
1b, Mig and CX3CL1.
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The discrepancies noted above in cytokine/chemokine
production following hMPV infection may reflect the
isolate of virus (laboratory-adapted versus primary isolate)
used in the various studies, differences in the cytokines
examined, the time points examined and methodological
read-outs (mRNA expression/protein concentration/intra-
cellular cytokine staining).
Chemokines are likely to play a role in regulating the
immune response by induction of local inflammation and
as chemoattractants for mononuclear cells. Both of these
effects predispose to effective innate and adaptive immune
responses. Such responses may play a significant role in the
clinical manifestations of hMPV and hRSV infection
observed in humans, and contribute to the less severe
disease induced by hMPV (Williams et al., 2006).
In this study, M2 CTL epitopes were used to evaluate cell-
mediated immunity, as they occur at a near-identical
location and with identical major histocompatibility
complex (MHC) class I anchor residues (i.e. MHC
restriction) in both hMPV and hRSV. We have previously
reported other similarities in immunogenic regions and
CTL-epitope sequences between hMPV and hRSV (Herd
et al., 2008), probably reflecting the taxonomic and
pathogenic relatedness of the two viruses.
Studies from our laboratory and others indicate that a
repertoire of hMPV-specific CTL responses is engendered
to a range of epitopes in humans (Herd et al., 2008) and
mice (Herd et al., 2006; Melendi et al., 2007). In humans,
the amino acid sequences of the identified CTL epitopes
are conserved amongst many, and in some cases all,
identified hMPV genotypes and strains (Herd et al., 2008),
suggesting that natural infection with a given strain might
engender cross-protection against others. A broad-rep-
ertoire response is likely to protect against the emergence
of putative escape mutants containing mutations in
individual epitopes. In humans, we have shown that an
hMPV-directed virus-specific memory response appears to
persist for at least several years following clinical hMPV
infection (Herd et al., 2008) [although it cannot be ruled
out that this may be due to subsequent subclinical
infection(s) reinforcing memory]. Nonetheless, it is clear
that, in humans, natural infection generates an IFN-c-
secreting CTL response. Whilst recall of this response does
not seem to prevent reinfection (as evidenced by recurrent
bouts of clinical infection throughout life), it may serve to
halt serious lower respiratory-tract disease in healthy
adults. This may not be the case in the very young, the
elderly or immunocompromised individuals.
In conclusion, we demonstrate a local T-cell response in
the lungs and airways of mice infected with the recently
identified respiratory pathogen hMPV. Along with our
earlier data reporting memory CTL responses in humans
(Herd et al., 2008), these results suggest that hMPV-
mediated CTL and cytokine/chemokine responses engen-
dered as a result of infection might contribute to control of
the virus, and provide a rationale for immunointervention.
Our results also demonstrate similarities in cellular
immune-response induction by infection with hMPV and
hRSV, a phylogenetically related virus with similar
biological and clinical features.
METHODS
Cell lines and epitope peptides. LLC-MK2 or HEp-2 cells
(ATCC) were used for virus production and quantification. Cell
Fig. 5. Immunoregulatory cytokines are upre-
gulated in lungs. Mice (n53 per group) were
infected intranasally with 105.7 p.f.u. of either
hMPV or hRSV or were uninfected (mock).
Cytokine concentration in lung homogenates
at 7 days p.i. was quantified by ELISA. Results
are shown as data points for individual mice,
mean±SEM. Cytokines are interferons and
chemokines are Mip-1a and IP-10.
Cellular immune response in hMPV infection
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lines were maintained in Opti-MEM (Invitrogen) or Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supplemented with
5% fetal bovine serum (FBS). P815 cells (H-2d, mastocytoma) (Sir
Albert Sakzewski Virus Research Centre, Australia) were used as
targets in cytotoxicity assays and were maintained in DMEM
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate,
20 mM HEPES, 50 mM b-mercaptoethanol, 100 IU penicillin ml21,
100 mg streptomycin ml21 and 10% FBS. The CTL epitopes ‘GYI’ and
‘SYI’ are both H2-Kd-restricted and occur at similar locations in the
M2 proteins of hMPV and hRSV, respectively (Table 1). These
epitopes were synthesized as peptides (.85% purity; Mimotopes),
dissolved at 10 mg ml21 in DMSO and diluted into assays as
required.
Virus preparation and quantification. hMPV [lineage A: AUS-001;
CAN97-83 (Hamelin et al., 2005)] was prepared in LLC-MK2 cells
and hRSV was prepared in HEp-2 cells, as described previously
(Alvarez et al., 2004; Herd et al., 2006; Woo et al., 2006 ). In brief,
virus was prepared by infecting cells in 225 cm2 flasks at an m.o.i. of
0.1. After adsorption for 2 h at 37 uC, the inoculum was removed
and the cells were washed before addition of fresh medium (40 ml).
For hMPV, trypsin (Invitrogen) was added during infection
(5 mg ml21) and every other day (2.5 mg ml21). Cultures were
incubated until 70–90% cytopathic effect was apparent, usually
within 7 days. Virus was obtained from the culture supernatant and
by freeze–thawing the cells. If necessary, virus was concentrated by
ultrafiltration using Centricon Plus-20 filter units (Millipore; 100 K
nominal molecular mass limit). Both viruses were quantified by
immunofocus assay as described previously (Herd et al., 2006; Woo
et al., 2006). In brief, subconfluent cell monolayers in a 96-well plate
were infected with 100 ml of serial dilutions (10-fold for virus, 4-fold
for lungs) and incubated for 2 h at 37 uC, before addition of 100 ml
fresh medium with 10% FBS. For hMPV, trypsin was added during
infection and then every other day. After 6 days, infected wells were
identified by using virus-specific antibody (anti-N monoclonal for
hMPV or polyclonal antibody for hRSV; Chemicon) followed by
species-appropriate developing reagents (anti-mouse or anti-goat,
horseradish peroxidase-labelled) and DAB substrate with metal
enhancer (Sigma). Results were expressed as TCID50 values. For
lung samples, the lower limit of detection was 101.6 TCID50 per left
lung.
Infection and sampling of mice. BALB/c mice (H-2d, female,
approx. 20 g) were supplied by the Animal Resources Centre (Perth,
Australia) and maintained under specific-pathogen-free conditions.
Mice were anaesthetized with ketamine/xylazine prior to intranasal
administration of virus (105 TCID50 in 60 ml) or Hanks’ balanced salt
solution (60 ml) as a control. Clinical illness was monitored and body
weight was recorded daily. At 5 days p.i., lungs were removed then
snap-frozen and stored at 270 uC before being homogenized for
determination of viral load. At 7 days p.i., lungs were collected for
histopathology and also for determination of cytokine/chemokine
levels.
Histopathology staining. Histopathological examination was per-
formed on lung samples isolated from hMPV-infected mice as
described by Hertz et al. (2001). Briefly, lung tissue representing the
central (bronchi–bronchiole) and peripheral (alveoli) airways was
fixed in 10% phosphate-buffered formalin, sectioned and stained
with haematoxylin and eosin.
Preparation of effector cells. At 7 days p.i., effector cells were
obtained from the airways (by BAL), whole lung tissue, regional
lymph nodes (mediastinal and tracheobronchial) and spleen for
determination of virus-specific CTL activity. Briefly, mice were
euthanized with ketamine/xylazine and then exsanguinated via the
abdominal aorta. For BAL, the thorax was opened, the diaphragm
pierced, the anterior ribcage removed and a small incision made
between the cartilage rings of the trachea. A 20G luer stub adaptor
needle was inserted and BAL was performed with 3 vols (0.8 ml each)
of Hanks’ balanced salt solution. For isolation of cells from
parenchyma, lungs were cut into 161 mm pieces and treated with
collagenase A (Roche; 4 mg per 2 ml per lung sample, 37 uC for 1 h
with agitation). Single-cell suspensions were then prepared from the
lungs, lymph nodes and spleen and by pressing through cell strainers
(100 mm) with a syringe plunger. At 21 days p.i., spleen cells were
obtained and restimulated in vitro with virus-specific peptide for
6 days.
Cytotoxic T-cell and intracellular cytokine mini-assays.
Cytotoxic T-cell activity was measured in a 51Cr-release assay
modified for small cell numbers, as described elsewhere (Ostler et
al., 2001). Briefly, effector cells (starting at 26105, or 56104 for
airway samples) were incubated with 51Cr-labelled target cells
(26103), with or without peptide (10 mg ml21), in a 96 ‘V’-well
plate in a total volume of 100 ml. After 6 h at 37 uC, 25 ml cell-free
supernatant was collected and radioactivity was determined. Peptide-
specific cytotoxicity was defined as (percentage cytotoxicity for targets
with peptide)2(percentage cytotoxicity for targets without peptide).
For intracellular cytokine analysis, cells (26105 or 56104) were
cultured for 6 h in a 96 ‘U’-well plate, with or without 10 mg peptide
ml21 in a volume of 0.2 ml. Brefeldin A (GolgiPlug; PharMingen) was
added at 1 ml ml21 for the last 4 h to facilitate intracellular
accumulation of cytokine. Cells were washed and surface-stained
with anti-CD8 [53-6.7, phycoerythrin (PE)/Cy5-labelled] or an isotype
control. Intracellular cytokine staining was performed with anti-IFN-
c (XMG1.2, PE-labelled) or an isotype control, using a CytoFix/
CytoPerm kit (PharMingen) according to the manufacturer’s
instructions. Cells were analysed on a Quanta SC flow cytometer
(Beckman Coulter).
Quantification of chemokine and cytokine mRNA expression in
lungs. Total RNA was isolated by using TRIzol (Invitrogen Life
Technologies) according to the manufacturer’s instructions, after
which 5 mg total RNA was reverse-transcribed using an oligo(dT)
primer and 260 U reverse transcriptase ml21 (Promega), according to
the manufacturer’s instructions. Real-time PCR was performed on a
Table 1. CTL epitopes at similar locations in the M2 proteins of hMPV and hRSV
Virus Protein Position* CTL epitopeD (abbreviation) MHC class I restriction Reference
hMPV M2-1 81–89 GYIDDNQSI (‘GYI’) H-2Kd Baumeister et al. (2003)
hRSV M2 82–90 SYIGSINNI (‘SYI’) H-2Kd Openshaw et al. (1990)
*Position is specified as the amino acid numbers of the M2-1 genes of hMPV (GenBank accession no. ACJ70116) and hRSV (GenBank accession
no. Q14974).
DMHC anchor residues are shown in bold.
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Rotor-Gene RG-3000 (Corbett Research), using Quantitect Primer
Assay kits (Qiagen), based on quantification of the SYBR green I
fluorescent dye. Specificity of the amplification was evaluated by a
melting-curve analysis of PCR products. Real-time PCR results were
expressed as ‘fold change in mRNA expression’, comparing infected
samples with the experimental controls (mock-inoculated+vehicle).
The Relative Expression Software Tool (REST) was used to calculate
differences in mRNA levels, which were first normalized to levels of
the housekeeping gene hypoxanthine–guanine phosphoribosyltrans-
ferase (HPRT).
ELISAs for mouse cytokines. The concentration of Mip-1a, IFN-a,
IP-10 and IFN-c in samples was determined by ELISA (R&D Systems)
according to the manufacturer’s instructions.
Statistical analysis.Data are presented as means±SEM. Mean values
were compared by Student’s t-test and P,0.05 was considered
significant.
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